Douglas Lin, MD PhD

355 posts

Douglas Lin, MD PhD banner
Douglas Lin, MD PhD

Douglas Lin, MD PhD

@DougLinMD

Senior Pathologist and Associate Medical Director at Foundation Medicine.

Boston, MA 加入时间 Ağustos 2017
604 关注1K 粉丝
Douglas Lin, MD PhD 已转推
Advanced Prostate Cancer Consensus Conference
Advanced Prostate Cancer Consensus Conference@APCCC_Lugano·
Emergence of BRCA Reversion Mutations in Prostate Cancer Prior to PARP Inhibitor Exposure: Clinical and Therapeutic Implications onlinelibrary.wiley.com/doi/10.1002/ca… BRCA1/2🧬 reversion mutations, which restore BRCA function and confer PARP inhibitor resistance, were identified in advanced #ProstateCancer both after and without prior PARP inhibitor exposure. In this retrospective liquid biopsy study, 30% of PARP-naïve patients with BRCA reversions had received chemotherapy and radiation, suggesting DNA-damaging therapies may promote reversion and primary resistance, supporting earlier PARP inhibitor use. @DougLinMD @MaxMaomaoYe @OGjoerup @RyonGraf @RichardHuangMD @DouglasMab3lt @DrRanaMcKay @OncoAlert 🚨 @silkegillessen @AOmlin @weoncologists
Advanced Prostate Cancer Consensus Conference tweet media
English
0
22
38
2.5K
Douglas Lin, MD PhD 已转推
Liang Cheng, MD
Liang Cheng, MD@LiangChengMD·
Have you seen this newly recognized WHO tumor entity? I’m delighted to share this comprehensive review just published  @Human_Pathology (PMID: 41475433), beautifully written by Gahie, Hui-Min, and my colleagues @BrownPathology   Endometrial gastric (gastrointestinal) -type mucinous adenocarcinoma (EGMA) is a rare histologic subtype of endometrial carcinoma that has recently included as a new WHO entity and is now recognized by the 2023 FIGO staging system as an aggressive histologic subtype. Previously, these tumors often overlapped diagnostically with endometrioid carcinomas showing mucinous differentiation; however, EGMA is now clearly established as a distinct clinicopathologic entity with more aggressive behavior. Morphologically, tumor cells show gastric and/or intestinal differentiation with variable cytologic atypia. Immunohistochemically, ER and PR are negative or only focally positive (<5%), while tumor cells express gastrointestinal markers, including CDX2, MUC6, HIK1083, and SATB2. Clinically, EGMA is associated with a higher likelihood of deep myometrial invasion, lymphovascular invasion, and lymph node metastasis.  At present, complete surgical resection - including hysterectomy with bilateral salpingo-oophorectomy, tumor debulking, with or without pelvic/paraaortic lymph node dissection -appears to be the most effective primary treatment. Adjuvant chemotherapy is also likely beneficial, particularly for higher-stage disease. This review emphasizes the importance of judicious use of immunohistochemistry, careful morphologic evaluation, and close correlation with clinical history to accurately diagnose EGMA and distinguish it from important mimics. 🔗 Full article is available at the following link: sciencedirect.com/science/articl…
Liang Cheng, MD tweet mediaLiang Cheng, MD tweet mediaLiang Cheng, MD tweet mediaLiang Cheng, MD tweet media
English
0
44
100
4.9K
Dana-Farber
Dana-Farber@DanaFarber·
Congratulations to @DrMDavids who was awarded the 2025 @CllSociety Clinical Scholar Award for his work: Optimizing Glofitamab Combination Therapy in Richter’s Transformation. Read more: bit.ly/4eZLQtP
English
11
3
15
1.8K
Douglas Lin, MD PhD 已转推
The Oncologist
The Oncologist@OncJournal·
Benchmark study evaluating adequacy and success rates of comprehensive genomic profiling in tissue and plasma samples in a real-world setting. @DougLinMD doi.org/10.1093/oncolo…
English
0
1
5
609
Douglas Lin, MD PhD 已转推
Monika Vyas
Monika Vyas@Mvgs1706·
Emerging questions and SWI/SNF deficient entities - excellent talk by Dr. Agaimy @pbpath @TheUSCAP #USCAP2025
Monika Vyas tweet mediaMonika Vyas tweet mediaMonika Vyas tweet media
English
1
16
24
1.8K
Douglas Lin, MD PhD 已转推
Elizabeth Montgomery, MD
Elizabeth Montgomery, MD@LizMontgomeryMD·
This awful-looking malignant neoplasm proved to be a malignant solitary fibrous tumor on molecular studies - I was not the one clever enough to order the STAT6, but it is patchy - the detection of the NAB2::STAT6 fusion was important.
Elizabeth Montgomery, MD tweet mediaElizabeth Montgomery, MD tweet mediaElizabeth Montgomery, MD tweet mediaElizabeth Montgomery, MD tweet media
English
3
19
73
3.4K
Douglas Lin, MD PhD
Douglas Lin, MD PhD@DougLinMD·
Como devia ser no Brasil: as duas torcidas rivais entrando pacientemente no estádio e arquibancadas sem violência.
Douglas Lin, MD PhD tweet media
Português
0
0
0
89
Douglas Lin, MD PhD
Douglas Lin, MD PhD@DougLinMD·
Our latest work on a pan-tumor validation of an NGS-based, FDA-approved MSI analysis. This NGS-based MSI method has high concordance to traditional MMR IHC and PCR assays and correctly identifies MSI-H tumors for treatment and response to pembrolizumab. nature.com/articles/s4169…
English
2
6
22
1.5K
Douglas Lin, MD PhD 已转推
Yüksel Ürün
Yüksel Ürün@DrYukselUrun·
A very relevant question for 🩸liquid biopsy: @ChristianRolfo et al. @IcahnMountSinai 🧬When can we trust a negative result from a ctDNA test and omit tissue biopsy? 🧬LB with ctDNA tumor fraction ≥1% accurately identifies true negative results in lung cancer, reducing the need for invasive tissue tests. For ctDNA TF <1%, follow-up tissue testing is needed! @oncoalert @CCR_AACR @geoff_oxnard @isliquidbiopsy @MCristofanill @ASCO aacrjournals.org/clincancerres/…
Yüksel Ürün tweet media
English
0
22
47
4.8K
Douglas Lin, MD PhD 已转推
USCAP
USCAP@TheUSCAP·
Interesting case from Dr. Michelle S. Hirsch. Diagnosis? 54 year old male with a 2.8 cm testicular mass. Join Dr. Hirsch at our January Diagnostic Challenges in Urologic Pathology course in Palm Springs for this and many other cases. my.uscap.org/app/program/kD…
USCAP tweet mediaUSCAP tweet mediaUSCAP tweet media
English
8
26
65
9.3K
Douglas Lin, MD PhD 已转推
Cruzeiro 🦊
Cruzeiro 🦊@Cruzeiro·
QUEM TEM MAIS, TEM SEIS 🏆🏆🏆🏆🏆🏆 A meta é a seguinte, Nação: 6 mil curtidas nesse tweet e a gente libera os #Bastidores. Bora?
Português
75
493
7.1K
148.2K
Douglas Lin, MD PhD
Douglas Lin, MD PhD@DougLinMD·
Our #digital #pathology publication from Foundation Medicine, capturing our work in training deep learning models to assess morphologies across lung adenocarcinoma resections and predict for EGFR mutation status, is published. Congrats James Pao and team! rdcu.be/c7368
English
0
0
3
330

发现

@MaxMaomaoYe @OGjoerup @RyonGraf @RichardHuangMD @DouglasMab3lt @DrRanaMcKay @OncoAlert @silkegillessen